230 related articles for article (PubMed ID: 30327432)
1. Comprehensive elucidation of the structural and functional roles of engineered disulfide bonds in antibody Fc fragment.
Zeng F; Yang C; Gao X; Li X; Zhang Z; Gong R
J Biol Chem; 2018 Dec; 293(49):19127-19135. PubMed ID: 30327432
[TBL] [Abstract][Full Text] [Related]
2. Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds.
Wozniak-Knopp G; Stadlmann J; Rüker F
PLoS One; 2012; 7(1):e30083. PubMed ID: 22272277
[TBL] [Abstract][Full Text] [Related]
3. Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products.
Kuglstatter A; Stihle M; Neumann C; Müller C; Schaefer W; Klein C; Benz J;
Protein Eng Des Sel; 2017 Sep; 30(9):649-656. PubMed ID: 28985438
[TBL] [Abstract][Full Text] [Related]
4. A C-terminal interdomain disulfide bond significantly stabilizes the Fc fragment of IgG.
Wozniak-Knopp G; Rüker F
Arch Biochem Biophys; 2012 Oct; 526(2):181-7. PubMed ID: 22483683
[TBL] [Abstract][Full Text] [Related]
5. Conformational and Colloidal Stabilities of Human Immunoglobulin G Fc and Its Cyclized Variant: Independent and Compensatory Participation of Domains in Aggregation of Multidomain Proteins.
Yageta S; Shibuya R; Imamura H; Honda S
Mol Pharm; 2017 Mar; 14(3):699-711. PubMed ID: 28186764
[TBL] [Abstract][Full Text] [Related]
6. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.
Ying T; Chen W; Feng Y; Wang Y; Gong R; Dimitrov DS
J Biol Chem; 2013 Aug; 288(35):25154-25164. PubMed ID: 23867459
[TBL] [Abstract][Full Text] [Related]
7. Hinge-Deficient IgG1 Fc Fusion: Application to Human Lactoferrin.
Shiga Y; Murata D; Sugimoto A; Oshima Y; Tada M; Ishii-Watabe A; Imai K; Tomii K; Takeuchi T; Kagaya S; Sato A
Mol Pharm; 2017 Sep; 14(9):3025-3035. PubMed ID: 28763236
[TBL] [Abstract][Full Text] [Related]
8. Effects of a reduced disulfide bond on aggregation properties of the human IgG1 CH3 domain.
Sakurai K; Nakahata R; Lee YH; Kardos J; Ikegami T; Goto Y
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1526-35. PubMed ID: 25748879
[TBL] [Abstract][Full Text] [Related]
9. Abolition of aggregation of CH
Oyama K; Ohkuri T; Ochi J; Caaveiro JMM; Ueda T
Biochem Biophys Res Commun; 2021 Jun; 558():114-119. PubMed ID: 33915325
[TBL] [Abstract][Full Text] [Related]
10. Structural characterization of a human Fc fragment engineered for extended serum half-life.
Oganesyan V; Damschroder MM; Woods RM; Cook KE; Wu H; Dall'acqua WF
Mol Immunol; 2009 May; 46(8-9):1750-5. PubMed ID: 19250681
[TBL] [Abstract][Full Text] [Related]
11. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface.
Teplyakov A; Zhao Y; Malia TJ; Obmolova G; Gilliland GL
Mol Immunol; 2013 Nov; 56(1-2):131-9. PubMed ID: 23628091
[TBL] [Abstract][Full Text] [Related]
12. Engineered human antibody constant domains with increased stability.
Gong R; Vu BK; Feng Y; Prieto DA; Dyba MA; Walsh JD; Prabakaran P; Veenstra TD; Tarasov SG; Ishima R; Dimitrov DS
J Biol Chem; 2009 May; 284(21):14203-10. PubMed ID: 19307178
[TBL] [Abstract][Full Text] [Related]
13. Thioether-bonded constructs of Fab'gamma and Fc gamma modules utilizing differential reduction of interchain disulfide bonds.
Kan KS; Anderson VA; Leong WS; Smith AM; Worth AT; Stevenson GT
J Immunol; 2001 Jan; 166(2):1320-6. PubMed ID: 11145716
[TBL] [Abstract][Full Text] [Related]
14. Domain-level stability of an antibody monitored by reduction, differential alkylation, and mass spectrometry analysis.
Liu H; Chumsae C; Gaza-Bulseco G; Goedken ER
Anal Biochem; 2010 May; 400(2):244-50. PubMed ID: 20152794
[TBL] [Abstract][Full Text] [Related]
15. [A stable conformer of IgG, prepared by an acidic influence: study by calorimetry, binding of the C1q complement component, and monospecific anti-IgG].
Kravchuk ZI; Vlasov AP; Liakhnovich GV; Martsev SP
Biokhimiia; 1994 Oct; 59(10):1458-77. PubMed ID: 7819387
[TBL] [Abstract][Full Text] [Related]
16. Crystal structures of immunoglobulin Fc heterodimers reveal the molecular basis for heterodimer formation.
Choi HJ; Seok SH; Kim YJ; Seo MD; Kim YS
Mol Immunol; 2015 Jun; 65(2):377-83. PubMed ID: 25743157
[TBL] [Abstract][Full Text] [Related]
17. Hierarchical formation of disulfide bonds in the immunoglobulin Fc fragment is assisted by protein-disulfide isomerase.
Vinci F; Catharino S; Frey S; Buchner J; Marino G; Pucci P; Ruoppolo M
J Biol Chem; 2004 Apr; 279(15):15059-66. PubMed ID: 14729662
[TBL] [Abstract][Full Text] [Related]
18. Disulfide Modified IgG1: An Investigation of Biophysical Profile and Clinically Relevant Fc Interactions.
Bahou C; Love EA; Leonard S; Spears RJ; Maruani A; Armour K; Baker JR; Chudasama V
Bioconjug Chem; 2019 Apr; 30(4):1048-1054. PubMed ID: 30855134
[TBL] [Abstract][Full Text] [Related]
19. Structural consequences of aglycosylated IgG Fc variants evolved for FcγRI binding.
Ju MS; Na JH; Yu YG; Kim JY; Jeong C; Jung ST
Mol Immunol; 2015 Oct; 67(2 Pt B):350-6. PubMed ID: 26153451
[TBL] [Abstract][Full Text] [Related]
20. Construction of a stability landscape of the CH3 domain of human IgG1 by combining directed evolution with high throughput sequencing.
Traxlmayr MW; Hasenhindl C; Hackl M; Stadlmayr G; Rybka JD; Borth N; Grillari J; Rüker F; Obinger C
J Mol Biol; 2012 Oct; 423(3):397-412. PubMed ID: 22846908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
